
Mirvetuximab Soravtansine
OncoPharm
00:00
Phase III Forward‑1: Negative Trial Results
John asks whether confirmatory trials exist and discusses Forward‑1, a negative phase 3 showing no PFS or OS benefit versus chemotherapy.
Play episode from 14:16
Transcript


